Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1193071 | 0.89 | EGLN1 (1.00) | EGLN1 | |
| SCHEMBL1193134 | 0.87 | EGLN1 (1.00) | EGLN1 | |
| SCHEMBL1193521 | 0.87 | EGLN1 (1.00) | EGLN1 | |
| SCHEMBL1192418 | 0.85 | EGLN1 (1.00) | EGLN1 | |
| SCHEMBL1193496 | 0.85 | EGLN1 (1.00) | EGLN1 | |
| SCHEMBL1192802 | 0.85 | EGLN1 (1.00) | EGLN1 | |
| SCHEMBL1193443 | 0.85 | EGLN1 (1.00) | EGLN1 | |
| SCHEMBL16551704 | 0.85 | EGLN1 (0.73) | EGLN1 | |
| SCHEMBL1192563 | 0.83 | EGLN1 (1.00) | EGLN1 | |
| SCHEMBL12875906 | 0.83 | EGLN1 (0.82) | EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11618744-B2 | Benzoimidazoles as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2023-04-04 | — | — | US | claimed |
| US-20210078978-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-03-18 | — | — | US | claimed |
| US-20180215732-A9 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-08-02 | — | — | US | claimed |
| US-20180022733-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-01-25 | — | — | US | claimed |
| EP-2294066-B9 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-03-11 | — | — | EP | claimed |
| US-20140256722-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-11 | — | — | US | claimed |
| EP-2294066-B1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-13 | — | — | EP | claimed |
| US-8759345-B2 | Benzoimidazoles as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-24 | — | — | US | claimed |
| US-20140005193-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (US) | 2014-01-02 | — | — | US | claimed |
| EP-2294066-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2011-03-16 | — | — | EP | claimed |
| US-20110046132-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-24 | — | — | US | claimed |
| WO-2009134750-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-05 | — | — | WO | claimed |
| US-11618744-B2 | Benzoimidazoles as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2023-04-04 | — | — | US | disclosed |
| US-11618744-B2 | Benzoimidazoles as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2023-04-04 | — | — | US | disclosed |
| US-20210078978-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-03-18 | — | — | US | disclosed |
| US-20210078978-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-03-18 | — | — | US | disclosed |
| US-20110046132-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-24 | — | — | US | disclosed |
| US-20110046132-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-24 | — | — | US | disclosed |
| WO-2009134750-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009134750-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11618744-B2 | Benzoimidazoles as prolyl hydroxylase inhibitors | P4HA1, PAH, EGLN3 | EGLN1 8/4885 |
| US-20110046132-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, PAH, EGLN3 | EGLN1 10/4885 |
| US-20180022733-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, PAH, EGLN3 | EGLN1 8/4885 |
| US-20140005193-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, PAH, EGLN3 | EGLN1 8/4885 |
| US-20180215732-A9 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, PAH, EGLN3 | EGLN1 8/4885 |
| US-20140256722-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, PAH, EGLN3 | EGLN1 8/4885 |
| US-20210078978-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, PAH, EGLN3 | EGLN1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.